Stifel Maintains Hold on Freeline Therapeutics, Raises Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha maintains a 'Hold' rating on Freeline Therapeutics (NASDAQ:FRLN) and raises the price target from $3 to $4.
August 16, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel maintains a 'Hold' rating on Freeline Therapeutics and raises the price target from $3 to $4. This could potentially lead to a slight increase in the stock's price.
The raised price target by Stifel indicates a positive outlook for Freeline Therapeutics. This could potentially lead to a slight increase in the stock's price in the short term. However, the 'Hold' rating suggests that the stock is expected to perform at the same level in the near future.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100